Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: Downregulation of multiple proapoptotic factors

Gene Therapy and Molecular Biology

Volumn 12, Issue 1, 2008, Pages 101-110

  Gomez, German G ^a,b   Hickey, Michelle J ^a   Tritz, Richard ^a   Kruse, Carol A ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adoptive immunotherapy; Apoptosis; Astrocytoma; Cellular therapy; CTL

Indexed keywords

EID: 50849126860     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Baxevanis CN, Reclos GJ, Gritzapis AD, Dedousis GV, Missitzis I, Papamichail M (1993) Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72, 491-501.
2. Cain K, Bratton SB, Cohen GM (2002) The Apaf-1 apoptosome: a large caspase-activating complex. Biochimie 84, 203-14.
3. Coldwell MJ, Mitchell SA, Stoneley M, MacFarlane M, Willis, AE (2000) Initiation of Apaf-1 translation by internal ibosome entry. Oncogene 19, 899-905.
4. Eramo A, Pallini R, Lotti F, Sette G, Patti M, Bartucci M, Ricci-Vitiani L, Signore M, Stassi G, Larocca LM, Crinò L, Peschle C, De Maria R (2005) Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction. Cancer Res 65, 11469-77.
5. Fakhrai H, Dorigo O, Shawler DL, Lin H, Mercola D, Black KL, Royston I, Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93, 2909-14.
6. Heshner M, Watkins LR, Redd JM, Kruse CA, Bellgrau D (1992) A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transpl 1, 307-12.
7. Fujimoto A, Takeuchi H, Taback B, Hsueh EC, Elashoff D, Morton DL, Hoon DS (2004) Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res 64, 2245-50.
8. Fulda S, Küfer MU, Meyer E, van Valen F, Dockhom-Dworniczak B, Debatin KM (2001) Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 20, 5865-77.
9. Gomez GG, Kruse CA (2006) Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol 10, 133-146.
10. Gomez GG, Kruse CA (2007) Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-β. J Immunother 30, 261-273.
11. Gomez GG, Read SB, Gerschenson LE, Santoli D, Zweifach A, Kruse CA ( 2004) Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors. Neuro-Oncol 6, 83-95.
12. Gomez GG, Varella-Garcia M, Kruse CA (2006) Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: cytogenetic and molecular cytogenetic characterization. Cancer Genet Cytogenet 165, 121-134.
13. Guha C, Guha U, Tribius S, Alfieri A, Casper D, Chakravarty P, Mellado W, Pandita TK, Vikram B (2000) Antisense ATM gene therapy: a strategy to increase the radio sensitivity of human tumors. Gene Ther 7, 852-8.
14. Khanna KK, Lavin MF, Jackson SP, Mulhern TD (2001) ATM, a central controller of cellular responses to DNA damage. Cell Death Differ 8, 1052-65.
15. Kruse CA, Beck LT (1997) Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. Biotech Appl Biochem 25, 197-205.
16. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO (1997) Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45, 77-87.
17. Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B, Bellgrau D (1990) Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci USA 87, 9577-81.
18. Kruse CA, Merchant RE (1997) Cellular Therapy of Brain Tumors - Clinical Trials. Advances in Neuro-Oncology II. P. L. Komblith and M. D. Walker. Armonk, N.Y., Futura Pub Co, 487-504.
19. Kruse CA, Rubinstein D (2001) Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors. Brain Tumor Immunotherapy. B. D. Liau LM, Cloughesy TF, and Bigner DD. Totowa, NJ, Humana Press, 149-170.
20. Kruse CA, Schiltz PM, Bellgrau D, Kong Q, Kleinschmidt-DeMasters BK ( 1994) Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neuro-Oncol 19, 161-8.
21. Lampson LA, Hickey WF (1986) Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. J Immunol 136, 4054-62.
22. Li YC, Tzeng CC, Song JH, Tsia FJ, Hsieh LJ, Liao SJ, Tsai CH, Van Meir EG, Hao C, Lin CC (2006) Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy. Clin Cancer Res 12, 2716-29.
23. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11, 5515-25.
24. Mitchell SA, Brown EC, Coldwell MJ, Jackson RJ, Willis AE (2001) Protein Factor Requirements of the Apaf-1 Internal Ribosome Entry Segment: Roles of Polypyrimidine Tract Binding Protein and upstream of N-ras. Mol Cellular Biology 21, 3364-74.
25. Moroni MC, Hickman ES, Denchi EL, Caprara G, Colli E, Cecconi F, Muller H, Helin K (2001) Apaf-1 is a transcriptional target for E2F and p53. Nature Cell Biology 3, 552-8.
26. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S (2000) T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6, 2209-18.
27. Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M, Gudeman S, Varia MA (1999) Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neuro-Oncol 45, 141-57.
28. Read SB, Kulprathipanja NV, Gomez GG, Paul DB, Winston KR, Robbins JM, Kruse CA (2003) Human alloreactive CTL interactions with gliomas and with those having upregulated HLA expression from exogenous IFN-gamma or IFN-gamma gene modification. J Int Cyt Res 23, 379-93.
29. Redd JM, Lagarde AC, Kruse CA, Bellgrau D (1992) Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother 34, 349-54.
30. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mitimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005) Radiotherapy plus concomitant and adjuvant temozolomide or glioblastoma. N Engl J Med 352, 987-96.
31. Thomas DA, Du C, Xu M, Wang X, Ley TJ (2000) DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. Immunity 12, 621-32.
32. Tibshirani R (2006) A simple method for assessing sample sizes in microarray experiments. BMC Bioinformatics 7, 106
33. Tribius S, Pidel A, Casper D (2001) ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. Int J Radiat Oncol Biol Phys 50, 511-23.
34. Virasch N, Kruse CA (2001) Strategies using the immune system for therapy of brain tumors. Hematol Oncol Clin No Am 15, 1053-71.
35. Walker PR, Saas P, Dietrich PY (1997) Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 158, 4521-4.
36. Watanabe T, Hirota Y, Arakawa Y, Fujisawa H, Tachibana O, Hasegawa M, Yamashita J, Hayashi Y (2003) Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma. Br Pathol 13, 431-9.
37. Yoshida H, Kong YY, Yoshida R, Elia AJ, Hakem A, Hakem R, Penninger JM, Mak TW (1998) Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94, 739-50.
38. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X (1997) "Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3." Cell 90, 405-13.